DOTMP SM-153

DB18484InvestigationalSmall molecule

DOTMP SM-153: Overview.

Mechanism: Pharmacologically active on Hydroxyapatite
Curator reviewed
Formula / weight: C₁₂H₂₉N₄O₁₂P₄Sm · 698.197 g/mol (avg)
Also known as: 153-Sm-DOTMP · 153sm-1,4,7,10-tetraazacyclododecane-1,4,7,10- tetramethylene-phosphonic acid · 153sm-dotmp · Cyclosam · Samarate(5-)-153sm, ((((1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl-.kappa.n1,.kappa.n4,.kappa.n7,.kappa.n10)tetrakis(methylene))tetrakis(phosphonato-.kappa.o))(8-))-, pentahydrogen
Code names: DOTMP SM-153 · SM-153-DOTMP

Resolves to

Compound

Structure

InChIKeyLNBUCNBAQQFTBL-GJNDDOAHSA-KSMILES[153Sm+3].OP(O)(=O)CN1CCN(CP(O)([O-])=O)CCN(CP(O)([O-])=O)CCN(CP(O)([O-])=O)CC1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of DOTMP SM-153, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.